Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Contact: Clinical Study Coordinator
Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225· Phase 3· Canadian Cancer Trials Group· Source
Contact: Osama Souied
Recruiting
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
NCT06358469· Canadian Cancer Trials Group· Source
Contact: Genevieve MacAulay Vacheresse
Recruiting
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079· Phase 2· Australasian Gastro-Intestinal Trials Group· Source
Contact: Dr Mussawar Iqbal
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Mussawar Iqbal (principal investigator)
Recruiting
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06182774· Phase 3· Canadian Cancer Trials Group· Source
Contact: Ibraheem Mohammed Othman
Not yet recruiting
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer
NCT06248749· Phase 3· University of Saskatchewan· Source
Contact: Maryam Al-Hayki
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Osama Souied (principal investigator)
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Haji I. Chalchal (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Muhammad H. Khan (principal investigator)
Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
NCT05180097· Phase 2· Canadian Cancer Trials Group· Source
Contact: Muhammad Salim
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Kimberly M. Hagel (principal investigator)
Active, not recruiting
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· Phase 2/3· NRG Oncology· Source
Active, not recruiting
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
NCT04786028· Phase 2· Canadian Myeloma Research Group· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· Phase 3· Leiden University Medical Center· Source
Contact: Maryam AlHayki
Active, not recruiting
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· Phase 3· NRG Oncology· Source
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756· SWOG Cancer Research Network· Source
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· Phase 3· University of Sydney· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
NCT03784755· Canadian Cancer Trials Group· Source
Active, not recruiting
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT03991819· Phase 1· University Health Network, Toronto· Source
Active, not recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· Phase 3· NRG Oncology· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
NCT03624543· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
NCT03715478· Phase 1/2· Canadian Myeloma Research Group· Source
Active, not recruiting
Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT03385655· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· Phase 2· NRG Oncology· Source
Active, not recruiting
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
NCT03410615· Phase 2· Canadian Cancer Trials Group· Source
Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03297606· Phase 2· Canadian Cancer Trials Group· Source
Contact: Kimberly Hagel
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Active, not recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· Phase 3· NRG Oncology· Source
Active, not recruiting
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106· Phase 2· Canadian Cancer Trials Group· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013· Phase 3· Canadian Cancer Trials Group· Source
Contact: Mussawar Iqbal
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436707· Phase 2· Canadian Cancer Trials Group· Source
Showing 50 of 64.